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Background: Abdominal aortic aneurysm (AAA) is associated with a prothrombotic diathesis that may increase the risk of
cardiovascular events. This diathesis is exacerbated in the short term by open aneurysm repair (OAR) and endovascular
aneurysm repair (EVAR). However, the effect of EVAR andOAR on coagulation and fibrinolysis in the medium and long
term is poorly understood. The purpose of this study was to investigate the medium-term effects of EVAR and OAR on
thrombin generation, neutralization, and fibrinolysis.
Methods: Prothrombin fragment (PF)1  2, thrombin antithrombin (TAT) complex, plasminogen activator inhibitor
(PAI) activity, and tissue-plasminogen activator (t-PA) antigen were measured in eight age-matched controls (AMCs), 29
patients with AAA immediately before (preoperatively) and 12 months after EVAR (post-EVAR), and in 11 patients at
a mean of 16 months after OAR (post-OAR).
Results: Preoperatively, PF1  2 levels were significantly higher in patients with AAAs than in AMC. PF1  2 levels
post-EVAR and post-OAR were significantly lower than preoperative values and similar to AMC. There was no
significant difference in TAT, PAI, or t-PA between AMC, AAA preoperatively, and post-EVAR. Post-OAR, PAI activity
was significantly higher than in preoperative patients.
Conclusions: AAA is associated with increased thrombin generation without upregulation of fibrinolysis. The prothrom-
botic, hypofibrinolytic diathesis observed in patients with AAA returns toward normal in the medium term after EVAR
and OAR, although there is a trend toward decreased fibrinolysis post-OAR. (J Vasc Surg 2013;57:103-7.)
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fAbdominal aortic aneurysm (AAA) is a chronic inflam-
matory condition associated with activation of coagula-
tion.1-4 The etiology of these changes is poorly understood
but may be related to smoking, the presence of peripheral
arterial disease leading to repeated lower limb ischemia and
reperfusion, and the biological activity of the aortic wall
and/or intraluminal thrombus.5-7 Previous studies have
suggested an association between the observed hemostatic
derangements, microvascular and macrovascular thrombo-
sis, and the development of complications such as myocar-
dial infarction, multiple organ failure, and venous and
arterial thromboembolism.8-10 Open aneurysm repair
(OAR) and endovascular aneurysm repair (EVAR) of AAAs
have been shown to be associated with an exacerbation of
these hemostatic derangements in the immediate perioper-
ative period.2,11,12 By contrast, the medium- and long-
term changes in coagulation and fibrinolysis after OAR and
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http://dx.doi.org/10.1016/j.jvs.2012.07.024VAR are poorly defined.13,14 The purpose of this study,
herefore, was to investigate, we believe for the first time,
he medium-term effects of EVAR and OAR on thrombin
eneration, neutralization, and fibrinolysis.
ETHODS
This study received ethical approval and all the patients
rovided fully informed written consent before participa-
ion. Patient demographics are shown in Table I.
atients
Group 1. Twenty-nine patients (27 men) of mean age
7 years (range, 55-89 years) were studied before (preop-
rative) and after EVAR (post-EVAR) for asymptomatic
AA of mean diameter 6.9 cm (range, 5.5-10 cm) between
uly 2008 and April 2009.
Group 2. Eleven patients (nine men) were studied a
ean of 16 months (range, 7-21 months) after OAR
post-OAR). Mean age at the time of blood sampling was
2 years (range, 58-85 years). All patients who underwent
AR were anatomically unsuitable for standard EVAR.
Group 3. Eight age-matched controls (AMC) (four
en) of mean age 73 years (range, 65-90 years) without
AA as documented by computed tomography (CT) scan,
erformed for the investigation of a nonvascular condi-
ion, were recruited. Specifically, five patients had normal
ollow-up CT scans 2 years after resection for colon cancer,
nd three patients had normal CT scans for nonspecific
103
a
P
f
i
v
n
g
v
v
R
v
R
w
a
o
a
t
h
w
a
p
w
r
s
t
l
c
ndard
bin-a
JOURNAL OF VASCULAR SURGERY
January 2013104 Abdelhamid et alabdominal pain. None of these patients was found to have
any significant pathology.
Exclusion criteria included vascular or nonvascular sur-
gical or endovascular procedure within the 3months before
EVAR or blood sampling; known inherited or acquired
thrombophilia; known disorders of fibrinolysis or platelet
function; and anticoagulation with vitamin K antagonists.
Blood sampling and assays. Venous blood samples
were taken from an antecubital fossa vein without tourni-
quet immediately before and 12 months after EVAR. Pa-
tients who underwent OAR and AMC had a single sample
taken. Samples were centrifuged for 15 minutes at 3500
rpm within 30 minutes of collection; plasma was isolated,
aliquoted, and stored at 80°C for later batch analysis.
Levels of prothrombin fragment (PF)1 2, a marker of
thrombin generation, (USCNLife Science,Wuhan, China)
and thrombin-antithrombin (TAT) complex, a marker of
thrombin neutralization14,15 (Enzygnost TAT micro, Sie-
mens Healthcare Diagnostics, Deerfield, Ill) were mea-
sured using enzyme-linked immunosorbent assays.
Tissue-plasminogen activator (t-PA) antigen (t-PA
Combi Actibind, Technoclone Ltd, Surrey, UK) and plas-
minogen activator inhibitor (PAI) activity (Technozym
PAI-1 Actibind, Technoclone Ltd, Surrey, UK) were as-
sayed as measures of fibrinolysis.
PF1 2, TAT, t-PA antigen, and PAI activity enzyme-
linked immunosorbent assays were performed using the
Triturus EIA Analyzer (Grifols, USA, LLC, Los Angeles,
Calif) according to the manufacturer’s instructions.
Statistical analysis. Analyses were performed using
Table I. Demographics of patients in the three groups
AMC group (n  8) EVAR g
Age (mean  SD) 73.1  8 77.
Sex (% men) 4 (50) 27
HT (%) 3 (37.5) 14
IHD (%) 1 (12.5) 16
CVA (%) 0 3
CKD (%) 1 (12.5) 14
AMC, Age-matched control; CKD, chronic kidney disease; CVA, cerebral v
ischemic heart disease; NS, not significant; OAR, open aortic repair; SD, sta
Table II. Laboratory results of different markers in the th
the manufacturer’s guidelines
Marker (normal range) AMC (n  8)
PF1  2 (0.4-1.1 nmol/L) 0.8 (0.7-1.4)
TAT (1-4.1 g/L) 4.6 (2.9-11.3)
PAI activity (1-7 U/mL) 6.4 (3.4-8.7)
t-PA antigen (2-8 ng/mL) 4.4 (3-4.8)
AMC, Age-matched control; EVAR, endovascular aneurysm repair; IQR, in
PF, prothrombin fragment; t-PA, tissue-plasminogen activator; TAT, throm
aP value .05.SPSS for Windows (version 16.0; SPSS Inc, Chicago, Ill) tnd GraphPad Prism 5 for Windows (version 5.03; Graph-
ad Software, San Diego, Calif). Data were log trans-
ormed, as they were not normally distributed. Median and
nterquartile range values were calculated for continuous
ariables, and categorical data were expressed as absolute
umbers with percentages. Differences between study
roups were assessed by the Fisher exact test for categorical
ariables and by Mann-Whitney U tests for continuous
ariables. Correlation was assessed by the Pearson method.
esults were considered statistically significant when P
alues were less than .05.
ESULTS
All EVAR procedures were undertaken uneventfully
ith AAA sac exclusion being confirmed by completion
ngiography and postprocedure CT. One patient devel-
ped acute coronary syndrome on the day of the operation
nd showed relatively higher PF1  2 levels. By 6 months,
hree patients developed unilateral graft limb stenosis and
ad required reintervention for claudication; two under-
ent balloon angioplasty and a third had common femoral
rtery endarterectomy and patch angioplasty. Two other
atients developed asymptomatic type II endoleaks, which
ere treated conservatively. None of the patients who
equired intervention or those who developed endoleak
howed significant procoagulant results. None of the pa-
ients developed deep vein thrombosis, pulmonary embo-
ism, or postimplantation inflammation syndrome.
All OARs were undertaken uneventfully without major
omplications and none of the patients required reinterven-
n  29) OAR group (n  11)
P value
(Fisher exact test)
.4 71.7  8.5 NS
1) 9 (81.8) .014
3) 6 (54.5) NS
2) 5 (45.5) NS
3) 1 (9.1) NS
3) 1 (9.1) .026
r accident; EVAR, endovascular aneurysm repair; HT, hypertension; IHD,
deviation.
roups (median and IQR). Normal range is according to
EVAR (n  29)
OAR (n  11)eoperative Post-EVAR
(1.6-3.5)a 1 (0.7-1.9) 0.8 (0.6-1.6)
(4.4-15.6) 7 (5.1-11) 5.6 (5-13.3)
(0.3-6.7) 5.7 (3.8-7.7) 7.5 (5.7-8.3)a
(2.6-4.4) 3.6 (2.4-4.5) 4 (3-5)
rtile range; OAR, open aortic repair; PAI, plasminogen activator inhibitor;
ntithrombin.roup (
6  7
(93.
(48.
(55.
(10.
(48.
ascularee g
Pr
2.2
6.2
4.9
3.4
terquaion in the period between surgery and blood sampling.
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Volume 57, Number 1 Abdelhamid et al 105One patient with AMC who had a CT scan for abdominal
pain was subsequently found to have cholelithiasis; no
other significant pathology was found in the remaining
seven patients.
Results from the PF1  2, TAT, t-PA, and PAI assays
are shown in Table II.
Thrombin generation and neutralization. Pre-
operatively, PF1  2 levels were significantly higher in
patients with AAA than in AMC (P  .0078). Post-EVAR
and post-OAR, PF1 2 levels had fallen significantly (P
.001 and P  .005, respectively). PF1  2 levels post-
EVAR were not significantly different from those observed
post-OAR and neither was significantly different from
AMC (Fig 1, A).
Median TAT levels in the AMC, preoperative (EVAR),
post-EVAR, and post-OAR samples were higher than the
normal range.However, there was no statistical significance
between the four groups (Fig 1, B).
Fibrinolysis. Preoperatively, PAI activity was not sig-
nificantly different from AMC or from the activity observed
post-EVAR. However, PAI activity was significantly ele-
vated in post-OAR samples when compared to preoperative
levels (P .03) (Fig 2,A). The t-PA antigen was within the
normal range in all samples with no significant difference
between the four groups (Fig 2, B).
DISCUSSION
EVAR is associated with significantly lower 30-day
perioperative morbidity and mortality than OAR.16-19
However, the fact that this survival benefit seems to be lost
over the next 6 to 12 months20,21 implies the presence of
excess mortality in the EVAR group over that time period.
The reasons for this remain poorly defined, but it has been
hypothesized that this “catch up” in mortality relates to
incomplete sac exclusion after EVAR and to a failure to
correct the preoperative prothrombotic, hypofibrinolytic
diathesis observed in AAA, which may predispose the pa-
tient to fatal thrombotic events such as myocardial infarc-
tion and stroke.
The present study confirms that AAA is associated with
increased thrombin generation (as demonstrated by ele-
vated PF1  2 levels). However, thrombin generation
returns to normal 1 year after EVAR and OAR. TAT levels
were also elevated but were similar between the four
groups. These data suggest that the hypercoagulable state
in patients with AAA is, in part, due to increased thrombin
generation. This might also suggest that thrombin neutral-
ization is not related to AAA and is related to other factors
like age, atherosclerosis, and smoking.5-7
Holmberg et al13 and Parry et al22 found higher PF1
2 and TAT levels in patients with AAA than in AMC.
Holmberg et al13 reported that post-OAR levels of PF1 
2 and TAT were lower than pre-OAR values. Wallinder et
al23 did not find any significant difference in PF1  2
between AMC and patients with either small or large AAA.
However, they reported significantly higher TAT in pa-
tients with large AAA. Aramoto et al24 described signifi-
cantly higher levels of TAT in patients with AAA and with wrterial occlusive disease, with no difference between those
wo groups. The reasons for the inconsistency between
tudies are unknown but may possibly be related to differ-
nces in the prevalence of peripheral arterial disease, male-
o-female ratio, and smoking rates between the different
ohorts.
In the present study, PAI activity before surgery was
ig 1. The horizontal lines represent the normal range according to
he manufacturer’s guidance. A, Prothrombin fragment (PF)1  2.
he preoperative group is significantly higher than the other groups.
, Thrombin-antithrombin (TAT) complex. There is no signifi-
ant difference between the four groups. AMC, Age-matched
ontrol; EVAR, endovascular aneurysm repair; OAR, open aortic
epair.ithin the normal range and the same as that observed in
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January 2013106 Abdelhamid et althe AMC. Post-EVAR, PAI activity was not different from
preoperative levels or those observed in AMC. Post-OAR,
PAI activity was significantly higher than in the preopera-
tive group but only slightly above the reference range
(Table II). This might lead to less fibrinolysis in this group
of patients. However, the minimal increase in PAI activity
above the normal range in post-OAR group might be
Fig 2. A, Plasminogen activator inhibitor (PAI) activity, 12
months post-open aortic repair (OAR) is significantly higher than
in the preoperative group. B, The tissue-plasminogen activator
(t-PA) antigen. There is no significant difference between the four
groups. AMC, Age-matched control; EVAR, endovascular aneu-
rysm repair.insignificant. Further studies are required to find out theignificance of this increase. The t-PA antigen levels were
ithin the normal range in all four groups even though,
iven the elevated PF 1  2 levels observed in the patients
ith AAA, one might have expected reduced PAI activity
nd high t-PA levels indicative of an increased, reactive,
brinolytic response.
Some previous reports have demonstrated that, in the
arly postoperative period, EVAR is associated with the
evelopment of a systemic inflammatory response and pro-
hrombotic coagulopathy equal to, if not greater than, that
bserved after OAR.14,25 However, the present study dem-
nstrates that the coagulation has largely returned to nor-
al 1 year after both EVAR and OAR, with no difference
eing observed between such patients and the AMC. Pres-
nt data seem to confirm that successful EVAR or OAR
esults in correction of the procoagulant diathesis observed
n patients with AAA before intervention.2,13 The cause of
hese presumably beneficial changes requires further study
ut might be due to removal (OAR) or exclusion (EVAR)
f the aortic wall and associated intraluminal thrombus
rom the circulation.13,21,26,27
In conclusion, the present study shows, we believe for
he first time, that in the medium-term, EVAR and OAR
esult in normalization of thrombin generation. Larger
tudies with longer follow-up are required to confirm the
resent findings, to explore the underlying mechanisms,
nd to determine whether the magnitude and duration of
he reduction in thrombin generation is associated with
mproved clinical outcomes.
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